AARTIDRUGS2023-10-012023-12-31 AARTIDRUGS2023-10-012023-12-31 AARTIDRUGS2023-10-012023-12-31in-bse-fin:OneOperatingExpenses01Member AARTIDRUGS2023-10-012023-12-31in-bse-fin:FourOperatingExpenses01Member AARTIDRUGS2023-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 524348 AARTIDRUGS NOTLISTED Aarti Drugs Limited Equity 2023-04-01 2024-03-31 2024-01-24 2024-01-17 INR Lakhs Third quarter 12:00:00 15:45:00 2024-01-24 2024-01-24 Not applicable Single segment Pharmaceuticals 2023-10-01 2023-12-31 Audited Standalone 5382100000.00 16800000.00 5398900000.00 3299300000.00 56400000.00 281700000.00 202400000.00 67500000.00 118000000.00 944900000.00 4970200000.00 428700000.00 0.00 428700000.00 107500000.00 5000000.00 112500000.00 0.00 316200000.00 0.00 0.00 0.00 0.00 316200000.00 0.00 316200000.00 316200000.00 0.00 919400000.00 10 3.44 3.44 0.00 0.00 3.44 3.44 0.00 0.00 0.00 1 ) The above results for the quarter and Period ended 31st December, 2023 have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 24th January, 2024.  2) The company has completed buyback of 6,65,000 equity shares of face value Rs.10/- representing up to 0.72% of the total number of Equity Shares of the Company at a price of Rs. 900/- per Equity Share (including premium of Rs. 890/- per Equity Share) payable in cash for an aggregate amount of up to Rs. 59,85,00,000/- (excluding transaction costs such as brokerage, Buyback tax, securities transaction tax, goods and service tax, stamp duty etc.)(“Buyback Size”) on 24th August, 2023. Post buyback Paid up Share Capital of the Company reduced to Rs. 91,93,50,000 divided into 9,19,35,000 Equity Shares of Rs.10/- each. 3) The Board of Directors have recommended interim dividend of Rs.1/- per Equity Share of Rs. 10/- each (10%) amounting to 9,19,35,000/- for the Quarter ended 31 st Decemebr,2023 4) Company has only one business segment i.e. pharmaceuticals. 5) Figures for the previous Quarter have been regrouped or rearranged wherever necessary 6)The aforesaid Audited Financial Results will be uploaded on the Company's website www.aartidrugs.com and will also be available on the website of BSE Limited www.bseindia.com and the National Stock Exchange of India Limited www.nseindia.com for the benefit of the shareholders and investors. Single segment 2023-04-01 2023-12-31 Audited Standalone 17073800000.00 30700000.00 17104500000.00 11209200000.00 249600000.00 122700000.00 609400000.00 220700000.00 353300000.00 2912200000.00 15677100000.00 1427400000.00 0.00 1427400000.00 345000000.00 25000000.00 370000000.00 0.00 1057400000.00 0.00 0.00 0.00 0.00 1057400000.00 0.00 1057400000.00 1057400000.00 0.00 919400000.00 10 11.50 11.50 0.00 0.00 11.50 11.50 0.00 0.00 0.00 Other Expenses 944900000.00 Other Expenses 2912200000.00